Healthy men test drug cocktail to uncover hidden interactions

NCT ID NCT06949124

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 31 times

Summary

This completed phase 1 study in 20 healthy men examined how SHR7280, a drug being developed for endometriosis and uterine fibroids, affects the body's processing of six other common drugs. Participants took SHR7280 alongside midazolam, warfarin, omeprazole, digoxin, and rosuvastatin to measure changes in drug levels and safety. The goal is to guide future dosing recommendations and avoid harmful interactions when SHR7280 is used with other medications.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Zhongnan hospital of Wuhan University

    Wuhan, Hubei, 430071, China

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SHR7280 tablets

What this could lead to

If successful, this study will help doctors understand how SHR7280 interacts with common medications, leading to safer dosing in future trials for endometriosis and uterine fibroids.

What could go wrong

This is an early-stage drug interaction study in just 20 healthy men, not patients. Results may not predict real-world effects in women with the target conditions.

Conditions

The condition(s) this trial relates to.

endometriosis leiomyoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.